^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
Excerpt:
...These include mutation in RAS, BRAF, PI3KCA; amplification of HER2, MET and loss of PTEN expression, all of which are implicated in resistance to anti-EGFR treatment....
Trial ID:
Source:
Title:
Biomarks of Resistance to Cetuximab in Colorectal Cancer
Excerpt:
...KRAS gene sequence - KRAS gene sequence; NRAS gene sequence - NRAS gene sequence; BRAF gene sequence - BRAF gene sequence; PIK3CA gene sequence - PIK3CA gene sequence; EGFR gene sequence - EGFR gene sequence; EGFR gene copy numbers - EGFR gene copy numbers; EGFR expression - EGFR expression; Her2 expression - Her2 expression; c-Met expression - c-Met expression; PTEN expression - PTEN expression; Progression-free survival - Progression-free survival; Overall survival - Overall survival; Rash - Rash; Diarrhea - Diarrhea; vomiting - vomiting; White blood cell count - White blood cell count; Platelet count - Platelet count; Hemoglobin - Hemoglobin; Red blood cell count - Red blood cell count...
Trial ID:
Less C2 evidence
Source:
Title:
350 - Co-expression and predictive value of HER family members for the response to therapy with cetuximab in patients with metastatic colorectal cancer
Published date:
03/10/2021
Excerpt:
...the response to treatment with cetuximab in patients with wild-type KRAS status mCRC….the cytoplasmic expression of HER2 was associated with better PFS.
